

MSG07: An International Cohort Study Comparing Epidemiology and Outcomes of Patients With *Cryptococcus neoformans* or *Cryptococcus gattii* Infections

John W. Baddley,¹ Sharon C.-A. Chen,^{2,3} Carrie Huisinigh,^{4,a} Kaitlin Benedict,^{5,b} Emilio E. DeBess,⁶ Eleni Galanis,^{7,8} Brendan R. Jackson,⁵ Laura MacDougall,⁸ Nicola Marsden-Haug,⁹ Hanna Oltean,⁹ John R. Perfect,¹⁰ Peter Phillips,^{7,11} Tania C. Sorrell,^{2,3,12} and Peter G. Pappas⁴

¹Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA; ²Centre for Infectious Diseases and Microbiology, Laboratory Services, Institute of Clinical Pathology and Medical Research, Westmead Hospital, The University of Sydney, Sydney, Australia; ³Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, Australia; ⁴Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA; ⁵Centers for Disease Control and Prevention, Atlanta, Georgia, USA; ⁶Oregon State Department of Health, Portland, Oregon, USA; ⁷School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada; ⁸British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada; ⁹Washington State Department of Health, Olympia, Washington, USA; ¹⁰Duke University Medical Center, Department of Medicine, Durham, North Carolina, USA; ¹¹St Paul's Hospital, Department of Medicine, Vancouver, British Columbia, Canada; and ¹²Westmead Institute for Medical Research, Infectious Diseases Group, Sydney, Australia

Background. Cryptococcosis due to *Cryptococcus neoformans* and *Cryptococcus gattii* varies with geographic region, populations affected, disease manifestations, and severity of infection, which impact treatment.

Methods. We developed a retrospective cohort of patients diagnosed with culture-proven cryptococcosis during 1995–2013 from 5 centers in North America and Australia. We compared underlying diseases, clinical manifestations, treatment, and outcomes in patients with *C. gattii* or *C. neoformans* infection.

Results. A total of 709 patients (452 *C. neoformans*; 257 *C. gattii*) were identified. Mean age was 50.2 years; 61.4% were male; and 52.3% were white. Time to diagnosis was prolonged in *C. gattii* patients compared with *C. neoformans* (mean, 52.2 vs 36.0 days; $P < .003$), and there was a higher proportion of *C. gattii* patients without underlying disease (40.5% vs 10.2%; $P < .0001$). Overall, 59% had central nervous system (CNS) infection, with lung (42.5%) and blood (24.5%) being common sites. Pulmonary infection was more common in patients with *C. gattii* than in those with *C. neoformans* (60.7% vs 32.1%; $P < .0001$). CNS or blood infections were more common in *C. neoformans*-infected patients ($P \leq .0001$ for both). Treatment of CNS disease with induction therapy of amphotericin B and flucytosine occurred in 76.4% of patients. Crude 12-month mortality was higher in patients with *C. neoformans* (28.4% vs 20.2%; odds ratio, 1.56 [95% confidence interval, 1.08–2.26]).

Conclusions. This study emphasizes differences in species-specific epidemiology and outcomes of patients with cryptococcosis, including underlying diseases, site of infection, and mortality. Species identification in patients with cryptococcosis is necessary to discern epidemiologic patterns, guide treatment regimens, and predict clinical progression and outcomes.

Keywords. cryptococcosis; *Cryptococcus gattii*; *Cryptococcus neoformans*.

Cryptococcus species are saprophytic yeast-like fungi responsible for a broad range of infections in humans. Pulmonary infection results from inhalation of the organism from an environmental source. Cryptococci have a propensity to infect the central nervous system (CNS), and meningoencephalitis is the most commonly recognized manifestation of severe disease [1].

The major species complexes that infect humans, *Cryptococcus neoformans* and *Cryptococcus gattii*, vary with regard to geographic distribution, populations affected, disease manifestations, and severity [2, 3]. *Cryptococcus neoformans* is ubiquitous and abundant in soil contaminated by pigeon droppings. Most often it causes opportunistic infection, typically meningoencephalitis in patients with AIDS, malignancy, or organ transplants and others receiving iatrogenic immunosuppression [1, 4, 5]. *Cryptococcus gattii* was previously regarded as being limited to primarily tropical and subtropical regions, with a major endemic focus in Australia. It has now been described throughout the world with emergence in Vancouver Island and British Columbia, Canada, and the Pacific Northwest of the United States (US), where it is now endemic, in the late 1990s and early 2000s [6–13]. Ecologically, this species is found in soil and in association with certain species of *Eucalypt* [3] and other tree species around the world [14–16].

Received 1 September 2020; editorial decision 22 March 2021; published online 27 March 2021.

^aPresent affiliation: AbbVie, North Chicago, Illinois, United States.

Presented in part: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, 5–9 September 2014, Washington, District of Columbia.

Correspondence: J. W. Baddley, University of Maryland School of Medicine, Division of Infectious Diseases, Institute of Human Virology, 725 W Lombard St, Baltimore, MD 21201, USA (jbaddley@ihv.umaryland.edu).

Clinical Infectious Diseases® 2021;73(7):1133–41

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

DOI: 10.1093/cid/ciab268

Small studies suggest that *C. gattii* tends to affect disproportionately patients with apparently normal immune systems compared with *C. neoformans* [9, 17–19]. Moreover, the frequency of clinical pulmonary disease in *C. gattii*-infected patients appears higher than in those infected with *C. neoformans* [19]. Development of intracranial and pulmonary cryptococcomas and need for ventricular shunting may be more frequent among patients with *C. gattii* infection, but the impact of species vs host characteristics on these disease manifestations and outcomes requires further elucidation [11, 19]. Data informing management and duration of antifungal therapy have either been generated from specific geographic regions, or involved only small patient cohorts, and are now dated [8, 10, 20]. Furthermore, because standard culture methods do not differentiate the 2 species, identification to species level has not been performed in many areas, limiting comparative studies [12, 21].

Recently reported *C. gattii* infections in the US Pacific Northwest and identification of sporadic human cases in nonendemic areas have stimulated discussion regarding comparisons of these 2 distinct *Cryptococcus* species. As part of a multi-institutional initiative, we compared risk factors, clinical manifestations, treatment, and outcomes of cryptococcosis among patients with *C. gattii* or *C. neoformans* infection in order to inform our understanding of the epidemiology and clinical progression and to guide patient management.

METHODS

Datasets and Study Population

This retrospective cohort study organized by the US Centers for Disease Control and Prevention (CDC) and Mycoses Study Group is based on a master dataset derived from 5 individual site datasets of patients with cryptococcosis. Contributing sites included the University of Alabama at Birmingham (1998–2010) [22]; Duke University Medical Center (1995–2009) [23]; British Columbia Centre for Disease Control (1999–2007) [8–10]; Washington State Department of Health and Oregon State Department of Health (2004–2011) [24]; and Westmead Hospital, The University of Sydney, Australia (1999–2013). Case inclusion required a culture-positive result from cerebrospinal fluid (CSF), blood, other body fluid, tissue, or respiratory sample (sputum, bronchoalveolar lavage fluid) with a compatible clinical and/or radiographic presentation. Species-specific culture methods were used to distinguish *C. gattii* from *C. neoformans* cases [25, 26].

Each site used a separate case report form for data collection. Australia included only patients initially diagnosed in the inpatient setting; all other sites included cases diagnosed in inpatient and outpatient settings. Prior to combining data from the 5 individual sites, similarity of case definitions, availability of comparable outcome information, structure of the different databases,

and the nomenclature of the respective variables were examined. A final list of variables and definitions was agreed upon by the investigators. These included demographic characteristics, clinical presentation, underlying medical conditions, antifungal treatment, laboratory values including CSF test parameters, imaging studies, and outcomes. To ensure consistency and accuracy in the process of master data set creation, individual-level data for 20 variables from site files were reviewed before final formulation of the master data set. Mortality was defined as all-cause at 3 or 12 months postdiagnosis. Duration of induction therapy of 1 week was defined as 1–9 days; 2 weeks as 10–20 days; 4–6 weeks as 21–49 days; and ≥ 7 weeks as 50–90 days.

We classified sites of involvement as follows: (1) CNS, which included meningeal and/or parenchymal brain involvement; (2) pulmonary, which included disease limited to the lungs, pleura, and/or pleural fluid; (3) bloodstream, which involved any isolation of *Cryptococcus* species in blood culture; and (4) other. Disseminated infection was defined as extrapulmonary infection. Patients may have had >1 site of involvement. A patient was classified with no underlying disease if no evidence of human immunodeficiency virus (HIV), transplantation, malignancy, neutropenia, chronic organ dysfunction, diabetes, corticosteroid use, immunosuppressant use, or other immunodeficiency was identified. Malignancy was defined as cancer diagnosed or treated within 6 months prior to diagnosis of cryptococcosis or recurrent/metastatic cancer. Time to diagnosis was defined by the number of days between the date of symptom onset and confirmed date of diagnosis.

Statistical Analysis

Characteristics for the overall cohort and for patients with infection due to *C. neoformans* or *C. gattii* were calculated using means and standard deviations, medians and interquartile ranges, or counts and percentages as appropriate. To analyze the relationship between independent variables and *Cryptococcus* species, univariate analyses were performed using χ^2 or Fisher exact test for categorical variables and analysis of variance or Wilcoxon rank-sum testing for continuous variables. Additional analyses of the relationship between lumbar puncture variables or sex and *Cryptococcus* species were adjusted by HIV infection. Two-sided *P* values < .05 were considered statistically significant. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between *Cryptococcus* species and outcomes of interest (eg, mortality, complications) with and without adjustment for age, sex, race, time to diagnosis from symptom onset, HIV, chronic lung disease, and site of infection. SAS version 9.3 software (SAS Institute, Cary, North Carolina) was used for all analyses. The study was approved by the institutional review boards (or equivalents) of all sites and the CDC.

RESULTS

In the master data set, 709 (452 *C. neoformans*; 257 *C. gattii*) patients had culture-positive cryptococcosis and were included in the final analyses (Table 1). Mean age of patients was 50.2 years; 61.4% were male and 59.0% were white. *Cryptococcus gattii* patients were older and more frequently female ($P < .01$ for both). After evaluating the relationship of sex and species and adjusting by HIV, female sex was associated with *C. gattii* infection ($P = .03$). Time to diagnosis of cryptococcosis was prolonged in *C. gattii*-infected patients (mean, 52.2 days for *C. gattii* vs 36.0 days for *C. neoformans*; $P < .003$). Overall, most patients (59.1%) had CNS infections, with lung (42.5%) and blood (24.5%) the next most commonly affected sites (Table 1). Pulmonary infection was more commonly associated with *C. gattii* infection (60.7% vs 32.1% for *C. neoformans*; $P < .0001$). In contrast, CNS, blood, or skin infections were more common in *C. neoformans*-infected patients ($P < .01$ for all).

Most patients (78.8%) had underlying disease and in general, those with *C. gattii* were less immunocompromised; for example, HIV infection (3.5% vs 38.5%; $P < .0001$) and solid organ transplantation (6.2% vs 25%; $P < .001$) were less frequent among *C. gattii*-infected patients, and there was a higher proportion without underlying disease (40.5% vs 10.2%; $P < .001$). Exceptions were malignancy (19.1% vs 11.7%; $P = .007$) and chronic lung disease (22.2% vs 8.4%; $P = .001$), which were more common in *C. gattii* patients. Among patients with malignancy, only nonhematologic malignancy was more common among *C. gattii* patients.

Among patients with CNS infection, headache (72.3%), vomiting (37.0%), and altered mental status (36.5%) were frequent clinical symptoms or signs (Table 2). Fever was present in 31% of patients. Symptoms and signs were similar among both patient groups, with the exceptions of altered mental status and nausea, which were significantly more common in *C. neoformans*-infected patients. In contrast, headache was more commonly associated with *C. gattii* infection (Table 2).

Computed tomography (CT) and magnetic resonance imaging (MRI) findings are summarized in Table 3. The most common lung abnormalities were mass lesions (56.9%), unilateral (38.3%), and bilateral nodules (22.8%). Multiple lobar

infiltrates were more common among *C. neoformans*-infected patients (13.0% vs 1.1%; $P = .002$). On baseline brain imaging (either CT or MRI) among 419 persons with CNS infection, 44 (10.1%) had hydrocephalus. Patients with *C. gattii* CNS disease were significantly more likely to present with brain mass lesions (cryptococcomas).

Lumbar puncture data were available for 419 patients with meningitis (Table 4). Mean or median CSF opening pressure was not significantly different, nor were baseline cryptococcal antigen titers (Table 4). However, mean CSF glucose (13.9 vs 43.5 mg/dL; $P < .001$) was lower, median white blood cell counts (119 vs 30/mm³; $P < .001$) were higher, and the percentage of patients with India ink positivity (78.2% vs 71.2%; $P = .002$) was greater in *C. gattii* vs *C. neoformans* infection. After adjusting for HIV, there were no additional significant differences identified (Table 2). In an analysis of CNS infection in patients without HIV (Supplementary Table 1), patients with *C. gattii* infection had lower mean CSF protein compared with *C. neoformans* patients ($P = .045$).

The treatment of cryptococcosis frequently consisted of an amphotericin B (AmB) formulation plus flucytosine for induction therapy (Table 5). For patients with CNS diseases, an AmB formulation plus flucytosine as initial therapy was administered to 76.4% of patients and proportions were similar by cryptococcal species. Lipid formulations of AmB were more commonly used in *C. gattii*-infected patients (50% vs 39.5%; $P = .046$). For patients with data available on duration of induction therapy ($n = 473$), duration was different by species, with a greater proportion of *C. gattii*-infected patients receiving prolonged (>4 weeks) induction therapy ($P < .001$).

All-cause mortality was 18.8% at 3 months and 25.5% at 12 months (Table 6). For the 12-month endpoint, mortality was higher among patients with *C. neoformans* (28.4% vs 20.2%; OR, 1.56 [95% CI, 1.08–2.26]). After adjustment for age, sex, race, time to diagnosis from symptom onset, HIV, chronic lung disease, and site of infection, the strength of association was similar but not significant (OR, 1.46 [95% CI, .86–2.46]). In subgroup analyses of patients with CNS cryptococcosis, 12-month mortality was also greater among *C. neoformans*-infected patients in crude analysis (26.8% vs

Table 1. Characteristics of Patients With Cryptococcosis

Characteristic	Total (N = 709)	<i>Cryptococcus neoformans</i> (n = 452)	<i>Cryptococcus gattii</i> (n = 257)	P Value
Location				
Australia	82 (11.9)	15 (3.3)	67 (26.1)	<.0001
British Columbia	111 (16.2)	0 (0.0)	111 (46.2)	
Duke University Medical Center	178 (25.9)	178 (39.4)	0 (0.0)	
Oregon/Washington	112 (16.3)	34 (7.5)	78 (30.4)	
University of Alabama	226 (31.9)	225 (49.8)	1 (0.4)	
Age, y, mean ± SD	50.2 ± 16.2	49.0 ± 15.7	52.5 ± 16.9	.0064
Time to diagnosis from symptom onset, d, mean ± SD	41.7 ± 65.5	36.0 ± 68.7	52.2 ± 57.7	.0032

Table 1. Continued

Characteristic	Total (N = 709)	<i>Cryptococcus neoformans</i> (n = 452)	<i>Cryptococcus gattii</i> (n = 257)	PValue
Sex				
Male	432 (61.4)	295 (66.0)	137 (53.3)	.0009
Female	272 (38.6)	152 (34.0)	120 (46.7)	
Race				
African American	197 (27.8)	192 (42.5)	5 (2.0)	<.0001
White	371 (52.3)	233 (51.6)	138 (53.7)	
Asian/Pacific Islander	25 (3.5)	7 (1.6)	18 (7.0)	
Aboriginal	20 (2.8)	0 (0.0)	20 (7.8)	
Other	16 (2.3)	13 (2.9)	3 (1.2)	
Unknown	80 (11.3)	7 (1.6)	73 (28.4)	
Site of infection^a				
Central nervous system	419 (59.1)	291 (64.4)	128 (49.8)	.0001
Pulmonary	301 (42.5)	145 (32.1)	156 (60.7)	<.0001
Blood	174 (24.5)	154 (34.1)	20 (7.8)	<.0001
Skin	18 (2.5)	18 (4.0)	0 (0.0)	.0012
Bone or joint	11 (1.6)	9 (2.0)	2 (0.8)	.34
Soft tissue	13 (1.8)	12 (2.7)	1 (0.4)	.039
Prostate	2 (0.3)	2 (0.4)	0 (0.0)	.54
Disseminated ^b	493 (69.5)	353 (78.1)	140 (54.5)	<.0001
Other	21 (3.0)	18 (4.0)	3 (1.2)	.034
Underlying diseases				
None	150 (21.2)	46 (10.2)	104 (40.5)	<.0001
Corticosteroids	242 (34.1)	174 (38.5)	68 (26.5)	.0012
HIV	183 (25.8)	174 (38.5)	9 (3.5)	<.0001
CD4 count, cells/ μ L, mean \pm SD	29.2 \pm 44.3	25.3 \pm 39.3	93.7 \pm 71.8	<.0001
CD4 count, cells/ μ L, median (IQR)	11 (5–32)	10 (5–27)	80 (40–160)	<.0018
Solid organ transplant	129 (18.2)	113 (25.0)	16 (6.2)	<.0001
Lung	19 (2.7)	15 (3.3)	4 (1.6)	.16
Heart	23 (3.2)	22 (4.9)	1 (0.4)	.0012
Liver	20 (2.8)	19 (4.2)	1 (0.4)	.0032
Kidney	70 (9.9)	60 (13.3)	10 (3.9)	<.0001
Pancreas	6 (0.9)	6 (1.3)	0 (0.0)	.092
Stem cell transplant	3 (0.4)	2 (0.4)	1 (0.4)	>.99
Malignancy ^c	102 (14.4)	53 (11.7)	49 (19.1)	.0074
Hematologic	49 (6.9)	31 (6.9)	18 (7.0)	.94
Nonhematologic	61 (8.6)	26 (5.8)	35 (13.6)	.0003
Lymphoma	27 (3.8)	16 (3.5)	11 (4.3)	.62
Leukemia	20 (2.8)	11 (2.4)	9 (3.5)	.41
Neutropenia	9 (1.3)	2 (0.4)	7 (2.7)	.013
Rheumatologic disease	31 (4.4)	18 (4.0)	13 (5.1)	.50
Lupus	7 (1.0)	3 (0.7)	4 (1.6)	.25
End-stage renal disease	19 (2.7)	16 (3.5)	3 (1.2)	.060
Renal insufficiency	102 (14.4)	82 (18.1)	20 (7.8)	.0002
Diabetes	116 (16.4)	78 (17.3)	38 (14.8)	.39
Sarcoidosis	14 (2.0)	11 (2.4)	3 (1.2)	.24
Liver disease	53 (7.5)	32 (7.1)	21 (8.2)	.60
Cirrhosis	32 (4.5)	23 (5.1)	9 (3.5)	.33
Chronic lung disease ^d	95 (13.4)	38 (8.4)	57 (22.2)	<.0001
COPD	27 (3.8)	7 (1.6)	20 (7.8)	<.0001
Pregnancy (among females)	8 (2.9)	4 (2.6)	4 (3.3)	.73
Idiopathic CD4 lymphopenia	3 (0.4)	1 (0.2)	2 (0.8)	.30

Data are presented as No. (%) unless otherwise indicated. Analysis of variance or Wilcoxon rank-sum testing and χ^2 or Fisher exact tests were used to compare continuous and categorical variables, respectively.

Abbreviations: COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; IQR, interquartile range; SD, standard deviation.

^aRepresents number of patients who had infection at that the site. Patients may have involvement of >1 site and may be represented more than once.

^bPatients may have >1 extrapulmonary site.

^cMalignancy was defined as cancer diagnosed or treated within 6 months prior to diagnosis of cryptococcosis or recurrent/metastatic cancer.

^dIncludes asthma, COPD, sarcoidosis, bronchiectasis, bronchiolitis, chronic bronchitis, chronic lung disease, cystic fibrosis, end-stage lung disease, emphysema, pulmonary fibrosis, pulmonary alveolar proteinosis, sarcoidosis, and reactive airway disease.

Table 2. Baseline Clinical Findings in Patients With Any Central Nervous System Cryptococcosis

Characteristic	Total (N = 419)	<i>Cryptococcus neoformans</i> (n = 291)	<i>Cryptococcus gattii</i> (n = 128)	PValue
Clinical presentation				
Headache	303 (72.3)	199 (68.4)	104 (81.3)	.0067
Vomiting	155 (37.0)	108 (37.1)	47 (36.7)	.94
Altered mental status	153 (36.5)	121 (41.6)	32 (25.0)	.0012
Nausea	145 (34.6)	119 (40.9)	26 (20.3)	<.0001
Fever	130 (31.0)	86 (29.6)	44 (34.4)	.33
Visual impairment	109 (26.0)	68 (23.4)	41 (32.0)	.063
Malaise/weakness	92 (22.0)	69 (23.7)	23 (18.0)	.19
Focal neurologic impairment	50 (11.9)	29 (10.0)	21 (16.41)	.061
Seizures	41 (9.8)	32 (11.0)	9 (7.0)	.21
Cranial nerve palsy	35 (8.4)	27 (9.3)	8 (6.3)	.30
Myalgias	26 (6.2)	14 (4.8)	19 (7.4)	.075

Data are presented as No. (%) unless otherwise indicated. χ^2 or Fisher exact test was used to compare categorical variables.

15.9%; OR, 1.94 [95% CI, 1.13–3.34]); but not significant after adjusted analysis (OR 1.99 [95% CI, .91–4.33]). Among patients with pulmonary infection only, mortality was similar between cryptococcal species. The complication of immune reconstitution inflammatory syndrome (IRIS) was significantly less common among *C. neoformans* patients in crude (3.6% vs 7.1%; OR, 0.49 [95% CI, .24–.97]) and adjusted analyses (OR, 0.28 [95% CI, .10–.82]). There was no significant difference in the proportion of patients with CNS disease receiving permanent ventricular shunt placement (*C. neoformans* 13.0%; *C. gattii* 25%; OR, 0.78 [95% CI, .45–1.33]).

DISCUSSION

Cryptococcosis remains an important cause of morbidity and mortality among many patient populations, especially immunocompromised persons. Because routine culture methods and cryptococcal antigen testing cannot distinguish species, it is very likely that cases have been misclassified as *C. neoformans* in prior epidemiologic studies. This study evaluated a cohort of patients with species-specific culture-positive cryptococcosis in order to compare characteristics of patients with *C. gattii* or *C. neoformans* infection. We identified several differences in the epidemiology and outcomes in the 2 groups: Specifically, among *C. gattii*-infected patients, symptom duration prior to diagnosis

Table 3. Baseline Imaging Results Among Patients With Pulmonary or Central Nervous System Cryptococcosis

Baseline Imaging Result	Total	<i>Cryptococcus neoformans</i>	<i>Cryptococcus gattii</i>	PValue
Chest imaging in pulmonary cryptococcosis	(n = 167)	(n = 77)	(n = 90)	
CT imaging				
Normal	3 (1.8)	2 (2.6)	1 (1.1)	.60
Single lobar infiltrate	20 (12.0)	9 (11.7)	11 (12.2)	.92
Multiple lobar infiltrate	11 (6.6)	10 (13.0)	1 (1.1)	.0020
Mass lesion	95 (56.9)	50 (64.9)	45 (50.0)	.052
Unilateral nodule	64 (38.3)	29 (37.7)	35 (38.9)	.87
Bilateral nodules	38 (22.8)	15 (19.5)	23 (25.6)	.35
Cavitation	9 (5.4)	4 (5.2)	5 (5.6)	>.99
Diffuse/interstitial	7 (4.2)	5 (6.5)	2 (2.2)	.25
Pleural effusion	22 (13.2)	11 (14.3)	11 (12.2)	.69
Brain imaging in CNS cryptococcosis				
CT imaging				
Normal	(n = 325)	(n = 219)	(n = 106)	
Normal	192 (59.1)	152 (69.4)	40 (37.7)	<.0001
Hydrocephalus	36 (11.1)	17 (7.8)	19 (17.9)	.0062
Mass lesion	32 (9.9)	7 (3.2)	25 (23.6)	<.0001
MRI				
Normal	(n = 127)	(n = 97)	(n = 30)	
Normal	63 (49.6)	56 (57.7)	7 (23.3)	.0010
Hydrocephalus	10 (7.9)	9 (9.3)	1 (3.3)	.45
Mass lesion	23 (18.1)	12 (12.4)	11 (36.7)	.0025

Data are presented as No. (%) unless otherwise specified. χ^2 or Fisher exact test was used to compare categorical variables. Chest imaging data were available from all sites except Australia.

Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging.

Table 4. Baseline Lumbar Puncture Results Among Patients With Any Central Nervous System Cryptococcosis

Lumbar Puncture ^a	No.	Total (N = 419)	<i>Cryptococcus neoformans</i> (n = 291)	<i>Cryptococcus gattii</i> (n = 128)	PValue	PValue ^b
Opening pressure, mm H ₂ O						
Mean ± SD	237	312 ± 149	314 ± 152	306 ± 138	.72	.90
Median (IQR)	237	300 (190–420)	280 (190–430)	310 (180–400)	.90	NA
WBCs/μL, mean ± SD	369	158 ± 339	115 ± 265	267 ± 460	<.0001	.014
WBCs/μL, median (IQR)	369	46 (9–150)	30 (6–104)	119 (44–360)	<.001	NA
% Polymorphonuclear leukocytes	136	21 ± 27	18 ± 26	37 ± 29	.002	.003
% lymphocytes	164	67 ± 27	70 ± 26	59 ± 27	.02	.032
Protein, mg/L, mean ± SD	372	112 ± 137	116 ± 133	100 ± 146	.31	.067
Glucose, mg/dL, mean ± SD	374	35 ± 30	44 ± 28	14 ± 23	<.0001	<.001
% India ink positive	269	197/269 (73.2)	136/191 (71.2)	61/78 (78.2)	.002	.009
% CSF culture positive	399	389/399 (97.5)	272/280 (97.1)	117/119 (98.3)	.73	.72
CSF CrAg, median (IQR) ^b	329	512 (64–1024)	512 (64–1024)	256 (128–1050)	.80	NA
CSF CrAg positive	329	319 (97.0)	225/235 (95.7)	94/94 (100)	.07	
Serum CrAg, median (IQR) ^b	254	512 (128–1024)	1024 (64–2048)	512 (128–1024)	.63	NA
Serum CrAg positive	254	250/254 (98.4)	169/173 (97.7)	81/81 (100)	.17	

Data are presented as No. (%) unless otherwise specified. Analysis of variance or Wilcoxon rank-sum testing and χ^2 test were used to compare continuous and categorical variables, respectively.

Abbreviations: CrAg, cryptococcal antigen; CSF, cerebrospinal fluid; IQR, interquartile range; NA, not applicable; SD, standard deviation; WBC, white blood cell.

^aBaseline lumbar puncture defined as up to 14 days before and 6 days after the date of diagnosis.

^bAdjusted for human immunodeficiency virus.

^cCrAg testing performed by latex agglutination.

was prolonged, patients were less immunocompromised, pulmonary disease was more common, all-cause 12-month mortality was lower, and IRIS was more common.

There has been an increasing interest in *C. gattii* infections over the past 2 decades due to the emergence of *C. gattii* in the US Pacific Northwest and western Canada and the identification of sporadic cases across Canada and the US [8, 10–13, 27, 28].

Moreover, previous comparisons of *C. gattii* and *C. neoformans* have described that *C. gattii* infection is more likely to occur in nonimmunocompromised hosts and typically with pulmonary rather than CNS disease [17–19]. It is important to note that *C. neoformans* and *C. gattii* produce diseases in both immunocompromised and immunocompetent hosts, although species frequency is different in the 2 general risk groups.

Table 5. Induction Antifungal Therapy Among Patients With Cryptococcosis

Antifungal Therapy (All Sites)	Total (N = 709)	<i>Cryptococcus neoformans</i> (n = 452)	<i>Cryptococcus gattii</i> (n = 257)	PValue
Any AmBd	291 (41.0)	201 (44.5)	90 (35.0)	.0014
Any LAmB	227 (32.0)	144 (31.9)	83 (32.3)	.90
Any flucytosine	361 (50.9)	250 (55.3)	111 (43.2)	.0019
Any AmB plus flucytosine	358 (50.5)	248 (54.9)	110 (42.8)	.0020
AmBd plus flucytosine	224 (31.6)	160 (35.4)	64 (24.9)	.0039
LAmB plus flucytosine	156 (22.0)	90 (19.9)	66 (25.7)	.075
Any CNS cryptococcosis	(n = 419)	(n = 291)	(n = 128)	
Any AmBd	251 (59.9)	175 (60.1)	76 (59.4)	.88
Any LAmB	179 (42.7)	115 (39.5)	64 (50)	.046
Any flucytosine	320 (76.4)	226 (77.7)	94 (73.4)	.35
Any AmB plus flucytosine	320 (76.4)	226 (77.7)	94 (73.4)	.35
AmBd plus flucytosine	203 (48.5)	147 (50.5)	56 (43.8)	.20
LAmB plus flucytosine	137 (32.7)	81 (27.8)	56 (43.8)	.0014
Duration of induction (all sites)	(n = 473)	(n = 331)	(n = 142)	
1 wk (1–9 d)	100 (21.1)	76 (23.0)	24 (16.9)	<.0001
2 wk (10–20 d)	240 (50.7)	186 (56.2)	54 (38.0)	
4–6 wk (21–49 d)	107 (22.6)	62 (18.7)	45 (31.7)	
≥7 wk (50–90 d)	26 (5.5)	7 (2.1)	19 (13.4)	

Data are presented as No. (%) unless otherwise indicated. Analysis of variance or Wilcoxon rank-sum testing and χ^2 or Fisher exact tests were used to compare continuous and categorical variables, respectively.

Abbreviations: AmB, amphotericin B (includes deoxycholate and lipid formulations); AmBd, amphotericin B deoxycholate; CNS, central nervous system; LAmB, lipid formulation of amphotericin B.

Table 6. Outcomes of Patients With Cryptococcosis

Outcomes	Total (N = 709)	<i>Cryptococcus neoformans</i> (n = 452)	<i>Cryptococcus gattii</i> (n = 257)	Unadjusted OR (95% CI)	Adjusted ^a OR (95% CI)
Mortality at 3 mo	131 (18.8)	89 (19.7)	42 (17.0)	1.20 (.80–1.80)	0.95 (.53–1.70)
Mortality at 12 mo	178 (25.5)	128 (28.4)	50 (20.2)	1.56 (1.08–2.26)	1.46 (.86–2.46)
IRIS present	34 (4.8)	16 (3.6)	18 (7.1)	0.49 (.24–.97)	0.28 (.10–.82)
Any CNS infection	(n = 419)	(n = 291)	(n = 128)		
Shunt placement	70 (22.4)	38 (13.0)	32 (25.0)	0.78 (.45–1.33)	1.26 (.58–2.72)
Mortality at 3 mo	69 (16.6)	54 (18.6)	15 (11.9)	1.69 (.91–3.12)	1.40 (.58–3.37)
Mortality at 12 mo	98 (23.5)	78 (26.8)	20 (15.9)	1.94 (1.13–3.34)	1.99 (.91–4.33)
Pulmonary infection only	(n = 204)	(n = 104)	(n = 100)		
Mortality at 3 mo	38 (18.6)	17 (16.4)	21 (21.0)	0.74 (.36–1.49)	0.46 (.17–1.29)
Mortality at 12 mo	50 (24.5)	27 (26.0)	23 (23.0)	1.17 (.62–2.23)	1.12 (.46–2.70)

χ^2 or Fisher exact test was used to compare categorical variables.

Abbreviations: CI, confidence interval; CNS, central nervous system; IRIS, immune reconstitution inflammatory syndrome; OR, odds ratio.

^aAdjusted for age, sex, race, time to diagnosis from symptom onset, human immunodeficiency virus, chronic lung disease, and site of infection.

An increased proportion of *C. neoformans* patients were of male sex. When adjusted by HIV infection, this association was attenuated, but remained significant. Patients differed in frequency of site of disease, with *C. gattii* patients having a greater proportion of patients with pulmonary disease, and fewer CNS or bloodstream infections. These differences are influenced by underlying diseases in our cohort [3, 17]. HIV-infected patients with *C. neoformans* infection, compared to other host groups, are more likely to have CNS or bloodstream infection but fewer pulmonary infections [22, 23, 29]. HIV-infected patients in this cohort were much more common among *C. neoformans* cases.

An important differentiating finding was the prolonged duration of symptoms prior to diagnosis among *C. gattii* cases. This may reflect a lower diagnostic suspicion among HIV-negative cases, where cancer may have been considered first; closer monitoring of patients with HIV who may be more involved in the healthcare system; or higher proportion of meningitis among HIV cases, leading to more acute presentations. Even though the overall proportion of *C. gattii* patients who were immunocompromised was less, 60% had an immunocompromising condition. *Cryptococcus gattii* cases also had fewer CNS and bloodstream infections and a greater proportion of pulmonary infections. Given the higher proportion of pulmonary-only disease among *C. gattii* patients and the associated nonspecific pulmonary symptoms, cryptococcosis may have been lower in the differential diagnosis and testing for cryptococcosis may have been delayed. *Cryptococcus gattii*-infected patients were more likely to have underlying chronic lung disease. Perhaps in some cases, cryptococcal infection may have been attributed to chronic lung diseases, delaying diagnosis. A difference in underlying diseases may also affect duration of symptoms, as prior studies have reported a longer duration of symptoms in non-HIV patients with *C. neoformans* infection [22, 23].

Clinical features among patients with CNS disease were similar. Headache was more common in patients infected with

C. gattii, whereas altered mental status and nausea were more common among *C. neoformans*-infected patients. These differences are not easily explained by the lumbar puncture results, where most CSF parameters were similar, including opening pressure at baseline. However, CSF white blood cell count was significantly higher and CSF glucose correspondingly lower among *C. gattii* patients. When adjusted for HIV infection, these species-specific differences did not change significantly. Furthermore, there were a greater number of cases of IRIS in *C. gattii* patients. Elevated white blood cells could reflect a unique feature of the host–pathogen interaction, or simply a greater proportion of nonimmunocompromised hosts with relatively intact inflammatory responses among *C. gattii* patients. However, among patients without HIV infection, elevated CSF white blood cell counts remained significantly greater among *C. gattii* patients.

Previous studies have described imaging findings that may help to differentiate *C. neoformans* or *C. gattii* infection [10, 18, 30]. Phillips et al studied 152 patients with *C. gattii* infection, 66% of whom had lung cryptococcomas. Among the 43 patients with CNS disease and available imaging studies, brain cryptococcomas were present in 18.6% and hydrocephalus in 6.9% [10]. Chen et al noted that brain cryptococcomas were more common among *C. gattii*- than *C. neoformans*-infected patients [2]. Hydrocephalus is described in up to 50% of *C. gattii* infections [2, 11, 17–19]. Our findings confirm these observations: First, on brain imaging with MRI or CT, *C. gattii*-infected patients were more likely to have mass lesions (cryptococcomas) and “normal” imaging was less common. In contrast, on lung imaging, mass lesions were more frequent in patients with *C. neoformans*.

Current treatment guidelines for CNS cryptococcosis recommend AmB formulations plus 5-flucytosine, with fluconazole recommended for mild to moderate pulmonary disease [1]. In our cohort, patients with *C. gattii* were more likely to receive

lipid preparations of AmB and induction therapy was longer. This may be a result of institutional-specific practice guidelines, where local experience in at least 1 site supports prolonged induction (6–8 weeks) for eradication of disease. In addition, treatment guidelines for nonimmunocompromised patients recommend longer courses of induction therapy and suppression for *C. gattii* infection, especially those who have large and multiple pulmonary or CNS cryptococcomas [1]. The specific preciseness of recommendations for treatment between *C. neoformans* and *C. gattii* cannot be improved by this retrospective, uncontrolled study. However, it supports present recommendations that induction, consolidation, and maintenance therapies are similar for both species and local experience may help guide lengths of this therapy.

Mortality in patients with cryptococcosis ranges from 8% to 50% and is related to underlying disease [2, 22, 31–37]. Typically, immunocompromised HIV-negative patients are older with a variety of underlying diseases and have increased mortality [22, 23, 35, 37]. In this study, *C. neoformans* was associated with a higher all-cause 12-month mortality. After adjusted analyses, the strength of association remained consistent, but the findings were no longer significant. This is likely related to a decrease in power after multivariable analysis; however, we were not able to collect and analyze data on mortality attributable to cryptococcosis or treatment course, which may further inform the association. The presence of IRIS was significantly less common among *C. neoformans* patients, even after adjustment for potential confounders.

Our findings should be interpreted in light of several limitations. Our master dataset was derived from several datasets from which patients had been enrolled in overlapping time periods and from different settings (ie, hospitalized, outpatients). Treatment regimens were not standardized, which may have affected overall outcomes. Although we only included variables in the master data set that were defined similarly in the individual data sets, there is a risk of misclassification. Some data (chest imaging, duration of therapy, clinical response, lumbar punctures) were not available from all patients or sites. Finally, for this study we have not considered the newest proposals relating to the further division of *Cryptococcus* into multiple species, as this discussion has developed since these data were collected [38]. However, a large dataset such as we present herein will be necessary if we are to discern relevant clinical differences, if any, among the newly proposed species classifications for cryptococci [11].

In summary, this description of a large collection of cases highlights differences in epidemiology and clinical outcomes of patients with cryptococcosis due to *C. neoformans* or *C. gattii*. In addition, we have identified that cryptococcal species may be associated with mortality. Our work supports the need for species-specific testing in patients with cryptococcosis to better define epidemiologic and clinical patterns, to guide appropriate

treatment regimens, and to predict clinical progression and outcome.

Supplementary Data

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Acknowledgments. The authors thank Gerald McGwin for assistance with the statistical analyses.

Disclaimer. The funder had no role in study design, data collection or analysis, or data interpretation for drafting of the manuscript. The findings and conclusion in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). The corresponding author had full access to all the data in the study and final responsibility for the decision to submit for publication.

Financial support. This work was supported by Merck, Inc.

Potential conflicts of interest. J. W. B.: consultation for Pfizer and Eli Lilly; data safety monitoring board for R-Pharm and Viela Bio. S. C.-A. C.: consultation for MSD Australia, Gilead Sciences, and F2G; untied educational grants from MSD Australia and F2G Ltd UK, outside the submitted work. H. O.: grants from CDC. John Perfect: research funding and consultation for Pfizer, Merck, Astellas, Amplyx, Apilli, Martinas, Scynexis, and Minnetronix; advisory board fees for F2G, Merck, Scynexis, Amplyx, Ampili, Minnetronix, and Martinas. P. P.: research grant support from Astella Pharma Canada and Pfizer Canada; training program grant support from Merck. P. G. P.: grant support from Merck, Astellas, Scynexis, Cidara, F2G, IMMY, Mayne, Amplyx, and Appili. All other authors report no potential conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2010; 50:291–322.
2. Chen SC, Slavin MA, Heath CH, et al; Australia and New Zealand Mycoses Interest Group (ANZMIG)-Cryptococcus Study. Clinical manifestations of *Cryptococcus gattii* infection: determinants of neurological sequelae and death. *Clin Infect Dis* 2012; 55:789–98.
3. Chen SC, Meyer W, Sorrell TC. *Cryptococcus gattii* infections. *Clin Microbiol Rev* 2014; 27:980–1024.
4. Jarvis JN, Bouille A, Loyse A, et al. High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. *AIDS* 2009; 23:1182–3.
5. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. *AIDS* 2009; 23:525–30.
6. Chambers C, MacDougall L, Li M, Galanis E. Tourism and specific risk areas for *Cryptococcus gattii*, Vancouver Island, Canada. *Emerg Infect Dis* 2008; 14:1781–3.
7. Bartlett KH, Cheng PY, Duncan C, et al. A decade of experience: *Cryptococcus gattii* in British Columbia. *Mycopathologia* 2012; 173:311–9.
8. Galanis E, Macdougall L, Kidd S, Morshed M, British Columbia *Cryptococcus gattii* Working Group. Epidemiology of *Cryptococcus gattii*, British Columbia, Canada, 1999–2007. *Emerg Infect Dis* 2010; 16:251–7.
9. MacDougall L, Fyfe M, Romney M, Starr M, Galanis E. Risk factors for *Cryptococcus gattii* infection, British Columbia, Canada. *Emerg Infect Dis* 2011; 17:193–9.
10. Phillips B, Galanis E, MacDougall L, et al; British Columbia *Cryptococcus gattii* Study Group. Longitudinal clinical findings and outcome among patients with *Cryptococcus gattii* infection in British Columbia. *Clin Infect Dis* 2015; 60:1368–76.
11. Harris JR, Lockhart SR, Debes E, et al. *Cryptococcus gattii* in the United States: clinical aspects of infection with an emerging pathogen. *Clin Infect Dis* 2011; 53:1188–95.

12. Harris JR, Lockhart SR, Sondermeyer G, et al. *Cryptococcus gattii* infections in multiple states outside the US Pacific Northwest. *Emerg Infect Dis* **2013**; *19*:1620–6.
13. DeBess E, Lockhart SR, Iqbal N, Cieslak PR. Isolation of *Cryptococcus gattii* from Oregon soil and tree bark, 2010–2011. *BMC Microbiol* **2014**; *14*:323.
14. Kidd SE, Chow Y, Mak S, et al. Characterization of environmental sources of the human and animal pathogen *Cryptococcus gattii* in British Columbia, Canada, and the Pacific Northwest of the United States. *Appl Environ Microbiol* **2007**; *73*:1433–43.
15. Kidd SE, Bach PJ, Hingston AO, et al. *Cryptococcus gattii* dispersal mechanisms, British Columbia, Canada. *Emerg Infect Dis* **2007**; *13*:51–7.
16. Acheson ES, Galanis E, Bartlett K, Mak S, Klinkenberg B. Searching for clues for eighteen years: deciphering the ecological determinants of *Cryptococcus gattii* on Vancouver Island, British Columbia. *Med Mycol* **2018**; *56*:129–44.
17. Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. *Clin Infect Dis* **1995**; *20*:611–6.
18. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of *Cryptococcus neoformans*. *Clin Infect Dis* **1995**; *21*:28–34; discussion 5–6.
19. Chen S, Sorrell T, Nimmo G, et al. Epidemiology and host- and variety-dependent characteristics of infection due to *Cryptococcus neoformans* in Australia and New Zealand. Australasian Cryptococcal Study Group. *Clin Infect Dis* **2000**; *31*:499–508.
20. Chen SC, Korman TM, Slavin MA, et al; Australia and New Zealand Mycoses Interest Group (ANZMIG) Cryptococcus Study. Antifungal therapy and management of complications of cryptococcosis due to *Cryptococcus gattii*. *Clin Infect Dis* **2013**; *57*:543–51.
21. Iverson SA, Chiller T, Beekmann S, Polgreen PM, Harris J. Recognition and diagnosis of *Cryptococcus gattii* infections in the United States. *Emerg Infect Dis* **2012**; *18*:1012–5.
22. Brizendine KD, Baddley JW, Pappas PG. Predictors of mortality and differences in clinical features among patients with cryptococcosis according to immune status. *PLoS One* **2013**; *8*:e60431.
23. Bratton EW, El Hussein N, Chastain CA, et al. Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. *PLoS One* **2012**; *7*:e43582.
24. Smith RM, Mba-Jonas A, Tourdjman M, et al. Treatment and outcomes among patients with *Cryptococcus gattii* infections in the United States Pacific Northwest. *PLoS One* **2014**; *9*:e88875.
25. Kwon-Chung KJ, Polachek I, Bennett JE. Improved diagnostic medium for separation of *Cryptococcus neoformans* var. *neoformans* (serotypes A and D) and *Cryptococcus neoformans* var. *gattii* (serotypes B and C). *J Clin Microbiol* **1982**; *15*:535–7.
26. Iqbal N, DeBess EE, Wohrle R, et al; *Cryptococcus gattii* Public Health Working Group. Correlation of genotype and in vitro susceptibilities of *Cryptococcus gattii* strains from the Pacific Northwest of the United States. *J Clin Microbiol* **2010**; *48*:539–44.
27. Lockhart SR, Iqbal N, Harris JR, et al. *Cryptococcus gattii* in the United States: genotypic diversity of human and veterinary isolates. *PLoS One* **2013**; *8*:e74737.
28. Gillece JD, Schupp JM, Balajee SA, et al. Whole genome sequence analysis of *Cryptococcus gattii* from the Pacific Northwest reveals unexpected diversity. *PLoS One* **2011**; *6*:e28550.
29. Lee YC, Wang JT, Sun HY, Chen YC. Comparisons of clinical features and mortality of cryptococcal meningitis between patients with and without human immunodeficiency virus infection. *J Microbiol Immunol Infect* **2011**; *44*:338–45.
30. Franco-Paredes C, Womack T, Bohlmeyer T, et al. Management of *Cryptococcus gattii* meningoencephalitis. *Lancet Infect Dis* **2015**; *15*:348–55.
31. Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes. *Clin Infect Dis* **2014**; *58*:736–45.
32. Bicanic T, Brouwer AE, Meintjes G, et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. *AIDS* **2009**; *23*:701–6.
33. Dismukes WE, Cloud G, Gallis HA, et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. *N Engl J Med* **1987**; *317*:334–41.
34. Pappas PG, Chetchotisakd P, Larsen RA, et al. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. *Clin Infect Dis* **2009**; *48*:1775–83.
35. George IA, Spec A, Powderly WG, Santos CAQ. Comparative epidemiology and outcomes of human immunodeficiency virus (HIV), non-HIV non-transplant, and solid organ transplant associated cryptococcosis: a population-based study. *Clin Infect Dis* **2018**; *66*:608–11.
36. Molloy SF, Kanyama C, Heyderman RS, et al; ACTA Trial Study Team. Antifungal combinations for treatment of cryptococcal meningitis in Africa. *N Engl J Med* **2018**; *378*:1004–17.
37. Martins LM, Wanke B, Lazéra Mdos S, et al. Genotypes of *Cryptococcus neoformans* and *Cryptococcus gattii* as agents of endemic cryptococcosis in Teresina, Piauí (northeastern Brazil). *Mem Inst Oswaldo Cruz* **2011**; *106*:725–30.
38. Kwon-Chung KJ, Bennett JE, Wickes BL, et al. The case for adopting the “species complex” nomenclature for the etiologic agents of cryptococcosis. *mSphere* **2017**; *2*:e00357–16.